Search

Displaying results 2741 - 2750 of 4300 in total
  1. Drug

    Lipegfilgrastim

    go.drugbank.com/drugs/DB13200
    Approved

    Since July 2013, lipegfilgrastim is marketed by the EMA as Lonquex for subcutaneously injection, where it is administered once following cytotoxic chemotherapy for each chemotherapy cycle in adult patients

  2. Drug

    Ponazuril

    go.drugbank.com/drugs/DB11452
    ExperimentalVet approved

    Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.

  3. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    Most currently approved antipsychotic medications work by affecting the neurotransmitters dopamine or serotonin. … For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed.

  4. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February

  5. Drug

    Ibuzatrelvir

    go.drugbank.com/drugs/DB19451
    Investigational

    Ibuzatrelvir is under investigation in clinical trial NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized but

  6. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.

  7. Drug

    VIT-100

    go.drugbank.com/drugs/DB05865
    Experimental

    VIT-100 was developed by ItherX Pharmaceuticals of San Diego.

  8. Drug

    FM-VP4

    go.drugbank.com/drugs/DB05449
    Investigational

    FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-choleste...

  9. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.

  10. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.